DDInter1762 DDInter1676
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Temozolomide {u} (Compound) treats {v} (Disease) brain cancer
Temozolomide {u} (Compound) binds {v} (Gene) CYP3A4
Temozolomide {u} (Compound) upregulates {v} (Gene) CAPN1
Temozolomide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Temozolomide {u} (Compound) downregulates {v} (Gene) ATP6V1D
Temozolomide {u} (Compound) causes {v} (Side Effect) Constipation
Temozolomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Temozolomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Temozolomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluorouracil
Temozolomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Temozolomide (Compound) treats brain cancer (Disease)
Temozolomide (Compound) binds CYP3A4 (Gene)
Temozolomide (Compound) upregulates CAPN1 (Gene)
Temozolomide (Compound) is included by Alkylating Activity (Pharmacologic Class)
Temozolomide (Compound) downregulates ATP6V1D (Gene)
Temozolomide (Compound) causes Constipation (Side Effect)
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab